Details for New Drug Application (NDA): 020859
✉ Email this page to a colleague
The generic ingredient in SONATA is zaleplon. There are twelve drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the zaleplon profile page.
Summary for 020859
Tradename: | SONATA |
Applicant: | Pfizer |
Ingredient: | zaleplon |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 5MG | ||||
Approval Date: | Aug 13, 1999 | TE: | AB | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
Approval Date: | Aug 13, 1999 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 020859
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | SONATA | zaleplon | CAPSULE;ORAL | 020859-001 | Aug 13, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pfizer | SONATA | zaleplon | CAPSULE;ORAL | 020859-002 | Aug 13, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription